RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer

mice. RNF180-correlated genes were involved in neuroactive ligand-receptor interaction, glycosaminoglycan binding, ECM structural constituents and organization, receptor ligand activity, cell adhesion, mRNA splicing and so forth in CRC. The expression of RNF180 may be used as a biomarker for the diagnosis, as a prognostic indicator, and as a gene therapy target of CRC.